Drugs News and Research

RSS

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

H&P Labs Inc. announced an agreement with Harvard University and Brigham and Women's Hospital to license two classes of compounds in order to develop an oral drug therapy against Ebola.

8 Jan 2015

Proteomics market expected to experience continual growth

The market for microarrays used to study the workings of proteins are in great demand, according to Kalorama Information. The healthcare market research publisher said "proteomics" instruments, reagents and testing are needed to discover new biomarkers and even new drugs, and that the market for them topped 5 billion dollars in 2013.

8 Jan 2015

Neuroscientists move one step closer to solving how learning and memory work

Researchers at Johns Hopkins have found out how a protein crucial to learning works: by removing a biochemical "clamp" that prevents connections between nerve cells in the brain from growing stronger.

8 Jan 2015

Johns Hopkins-led study offers strategy to eradicate HIV

Luring dormant HIV out of hiding and destroying its last cure-defying holdouts has become the holy grail of HIV eradication, but several recent attempts to do so have failed. Now the findings of a Johns Hopkins-led study reveal why that is and offer a strategy that could form a blueprint for a therapeutic vaccine to eradicate lingering virus from the body.

8 Jan 2015

American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

Migraine affects 36 million Americans, can have a major impact on patients' quality of life, and even on their relationships. The World Health Organization estimates that migraine is the third most prevalent medical disorder in the world, the 4th most disabling among women and the 7th most disabling overall.

8 Jan 2015

Debiopharm receives FDA Fast Track designation for anti-infectious agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced that the US Food and Drug Administration granted Fast Track designation to its anti-infectious agent Debio 1450, a highly potent antibiotic specifically active against all Staphylococcus species.

8 Jan 2015

Improving headache treatment could reduce health care spending, new study suggests

Each year more than 12 million Americans visit their doctors complaining of headaches, which result in lost productivity and costs of upward of $31 billion annually. A new study by researchers from Beth Israel Deaconess Medical Center suggests some of that cost could be offset by physicians ordering fewer tests and an increased focus on counseling about lifestyle changes.

8 Jan 2015

Research findings could lead to new drug design for neurological diseases

A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.

8 Jan 2015

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance to testosterone-blocking drugs used to treat prostate cancer.

8 Jan 2015

Healthplex & Nutraceutical China 2015 to be held in Shanghai, China

From 24-26 June 2015, Healthplex & Nutraceutical China (HNC) will return to Shanghai, China, to serve the Asian health industry. This year, the event will take place on a larger scale, with more exhibitors and business opportunities for those in attendance.

7 Jan 2015

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax Pharmaceuticals, Inc., (Waltham, Mass.; president and CEO: Arlene M. Morris, "Syndax") today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea.

7 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100.

7 Jan 2015

More insight into influence of obesity on distribution, elimination of drugs needed, say experts

Doctors and pharmacists often do not take obesity into account when prescribing medication. For this, more insight into the influence of obesity on the distribution and elimination of drugs is of the utmost importance. This is emphasized by Catherijne Knibbe in the most recent issue of the Annual Review of Pharmacology and Toxicology.

7 Jan 2015

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

An international team of researchers has developed a drug delivery technique that utilizes graphene strips as "flying carpets" to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.

7 Jan 2015

UCLA researchers develop method that defines unique stages of reprogramming skin cells

In a groundbreaking study that provides scientists with a critical new understanding of stem cell development and its role in disease, UCLA researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research led by Dr. Kathrin Plath, professor of biological chemistry, have established a first-of-its-kind methodology that defines the unique stages by which specialized cells are reprogrammed into stem cells that resemble those found in the embryo.

7 Jan 2015

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.

6 Jan 2015

LEO Pharma submits NDA for aerosol foam formulation to treat patients with plaque psoriasis

LEO Pharma announces it has submitted a New Drug Application (NDA) for calcipotriene and betamethasone dipropionate aerosol foam, 0.005%/0.064%, to the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis.

6 Jan 2015

Drugs News and Research

FDA approves RYTARY for Parkinson's disease treatment

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

Proteomics market expected to experience continual growth

Neuroscientists move one step closer to solving how learning and memory work

Johns Hopkins-led study offers strategy to eradicate HIV

American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

Debiopharm receives FDA Fast Track designation for anti-infectious agent Debio 1450

Improving headache treatment could reduce health care spending, new study suggests

Research findings could lead to new drug design for neurological diseases

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

Healthplex & Nutraceutical China 2015 to be held in Shanghai, China

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Using HIV drugs to treat AMD: an interview with Dr Mark Young

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

More insight into influence of obesity on distribution, elimination of drugs needed, say experts

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

UCLA researchers develop method that defines unique stages of reprogramming skin cells

EnGeneIC closes oversubscribed Series B financing

LEO Pharma submits NDA for aerosol foam formulation to treat patients with plaque psoriasis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News